RxDoctor Payments Data

Kara Warshaw

Psychiatric/Mental Health · Sulphur, LANPI 1942290200

Payments from drug & device makers

$4,000in general payments, 2019–2025

Across 216 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$612
  • Neurocrine Biosciences, Inc.$470
  • AbbVie$404
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$359
  • Alkermes, Inc.$357
  • Supernus Pharmaceuticals, Inc.$328
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,97699%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,000 in reported general payments places this provider in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$253,772
Invega SustennaPaliperidone Palmitate18$66,392
RexultiBrexpiprazole28$40,154
Abilify MaintenaAripiprazole12$37,123
VraylarCariprazine Hcl19$25,939
TrintellixVortioxetine Hydrobromide22$11,069
Lurasidone Hcl49$6,441
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$6,415
Clozapine36$2,560
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine52$1,921
Quetiapine Fumarate142$1,130
Oxcarbazepine45$979
Hydroxyzine Pamoate55$888
Duloxetine Hcl100$863
Buspirone Hcl81$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$470$253,77231 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$612$77,27640 claims
Johnson & JohnsonInvega Sustenna$131$66,39218 claims
AbbVieVraylar$404$25,93919 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$21$11,06922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Sulphur

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →